Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

Oncogene - 4 Aug 2005

Jebar Adel H, Hurst Carolyn D, Tomlinson Darren C, Johnston Colin, Taylor Claire F, Knowles Margaret A

Abstract excerpt

Fibroblast growth factor receptor 3 (FGFR3) mutations are frequent in superficial urothelial cell carcinoma (UCC). Ras gene mutations are also found in UCC. As oncogenic activation of both FGFR3 and Ras is predicted to result in stimulation of the mitogen-activated protein kinase (MAPK) pathway, we hypothesized that these might be mutually exclusive events. HRAS mutation has been widely studied in UCC, but all...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neoplasm Invasiveness
Share to Protein-Tyrosine Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Transitional Cell

Share to Genes, ras

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Receptors, Fibroblast Growth Factor

Share to Tumor Cells, Cultured

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 15897885
DOI: 10.1038/sj.onc.1208705

Genes

FGFR3
HRAS
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.PMID 15897885Read ↗

Oncogenic Activation of Fibroblast Growth Factor Receptor-3 and RAS Genes as Non-Overlapping Mutual Exclusive Events in Urinary Bladder Cancer.Semantic proximity Read ↗

The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancerSemantic proximity Read ↗

Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.Semantic proximity Read ↗

FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma.Semantic proximity Read ↗

Fibroblast growth factor receptor-3 in urothelial tumorigenesis.Semantic proximity Read ↗

FGFR3 – a Central Player in Bladder Cancer Pathogenesis?Semantic proximity Read ↗

Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.Semantic proximity Read ↗

FGFR3 Mutations in Urothelial Carcinoma: A Single-Center Study Using Next-Generation SequencingSemantic proximity Read ↗

Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors.Semantic proximity Read ↗

Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.Semantic proximity Read ↗

Molecular intricacies of upper tract urothelial carcinoma and their relevance for therapy considerations.Semantic proximity Read ↗

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.